HNF-1β在胰腺导管腺癌中的表达及其诊断价值

Expression of HNF-1β in pancreatic ductal adenocarcinoma and its diagnostic value

目的检测肝细胞核因子1β(hepatocyte nuclear factor 1β,HNF-1β)在胰腺导管腺癌(pancreatic ductal adenocarcinoma,PDAC)组织中的表达并探讨其诊断价值。方法收集2021-01—2023-0149例PDAC,采用免疫组化EnVision两步法检测HNF-1β、CK7、CK20、PAX-8、GATA-3、NapsinA、TTF1、ER、PR、NKX3.1和RCC的表达情况,比较各种肿瘤标记物表达的阳性率。结果HNF-1β阳性率为85.7%(42/49),其中45.2%(19/42)的病例为强阳性,14.3%(6/42)的病例为中等阳性,40.5%(17/42)的病例为弱阳性。CK7阳性率为83.7%(41/49)。CK20阳性率为4.1%(2/49)。PAX-8、GATA-3、Napsin A、TTF1、ER、PR、NKX3.1和RCC均为阴性表达,阳性率为0(0/49)。结论HNF-1β与其他谱系特异性的肿瘤标志物联合使用,可有助于PDAC的诊断和与其他来源的腺癌的鉴别诊断。

Objective To investigate the expression of Hepatocyte nuclear factor 1β(HNF-1β) in pancreatic ductal adenocarcinoma(PDAC) and its diagnostic value. Methods 49 cases of PDAC were collected from January 2021 to January 2023, and the expressions of HNF-1β, CK7, CK20, PAX-8, GATA-3, NapsinA, TTF1, ER, PR, NKX3.1 and RCC were detected by immunohistochemical EnVision method. The positive rates of various tumor markers were compared.Results The positive rate of HNF-1β was 85.7%(42/49), of which 45.2%(19/42) cases were strongly positive, 14.3%(6/42) cases were moderately positive, and 40.5%(17/42) cases were weakly positive. The positive rate of CK7 was 83.7%(41/49). The positive rate of CK20 was 4.1%(2/49). PAX-8, GATA-3, Napsin A, TTF1, ER, PR, NKX3.1 and RCC were all negative, and the positive rate was 0%(0/49). Conclusion HNF-1β combined with other lineage-specific tumor markers may be helpful in the diagnosis of PDAC and differential diagnosis from adenocarcinoma of other origin.